Document is current
Any future updates will be listed below
-
Authors
Ghosh, Auyon J.
Coyne, Liam P.
Panda, Sanchit
Menon, Aravind A.
Moll, Matthew
Archer, Michael A.
Wallen, Jason
Middleton, Frank A.
Hersh, Craig P.
Glatt, Stephen J.
Hess, Jonathan L.
-
Funding
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K08HL168205, K08HL159318, R01HL166231)
National Institute of Mental Health (R21MH126494, R21MH126494)
National Institute on Aging (R01AG064955)
National Institute of Neurological Disorders and Stroke (R01NS128535)
- License Information
-
More Information
Article History
Received: 25 October 2024
Accepted: 27 February 2025
First Online: 10 March 2025
Declarations
:
: This study was approved by the SUNY Upstate Institutional Review Board (approval #387215-47) and all patients provided written informed consent. The COPDGene study was approved by the Mass General Brigham Institutional Review Board (approval #2007P000554) and all patients provided written informed consent.
: Not applicable.
: AJG has received consulting fees from TDA Research, Inc. AAM has received consulting fees from Kinevant Sciences and fees for lectures from the France Foundation. MM has received consulting fees from 2ndMD, TheaHealth, TriNetX, Verona Pharmaceuticals, and Sanofi, payment for expert case review, and fees for lectures from the American and New York State Thoracic Societies. CPH has received grant support from the Alpha-1 Foundation, Bayer, Boehringer-Ingelheim, and Vertex Pharmaceuticals, and consulting fees from Apogee Therapeutics, Chiesi, Ono Pharma, Sanofi, Takeda, and Verona Pharmaceuticals. JLH has received grant support from the CNY Community Foundation and fees for lectures from the Schizophrenia International Research Society.
